Norgine Expands Its Hepatology Portfolio with Exclusive Licensing Agreement

In a significant move to enhance its specialty pharmaceutical offerings, Norgine, a leading European pharmaceutical company, has secured an exclusive licensing agreement with Vir Biotechnology. This deal allows Norgine to market the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) across Europe, Australia, and New Zealand, highlighting its commitment to addressing unmet medical needs in hepatology.

The licensing agreement is expected to involve an initial payment of 55 million euros to Vir Biotechnology, with potential milestone payments totaling up to 495 million euros, depending on regulatory and commercial achievements. Additionally, Vir will earn tiered royalties ranging from 15% to 20% based on net sales in the designated territories. This partnership reflects a comprehensive strategy to bring innovative solutions to patients suffering from the challenges posed by hepatitis delta chronic infections.

Norgine's CEO, Janneke van der Kamp, commented on the agreement, stating that it reaffirms Norgine's extensive expertise in hepatology and specialized care. She emphasized that such collaborations not only augment their portfolio but also strengthen Norgine's position as a preferred partner for companies seeking reliable collaboration in Europe, Australia, and New Zealand.